Skip to main content

Table 5 Subgroup analysis of efficacy and safety according to tumor type and ICI therapy

From: Safety and efficacy of immune checkpoint inhibitors (ICIs) in cancer patients with HIV, hepatitis B, or hepatitis C viral infection

Tumor Types
(N)
Co-infection
(N)
Anti-PD-(L)1 MonotherapyAnti-PD-(L)1 plus Chemotherapy
ORRa
N (%)
Any grade irAEs N (%)Grade ≥ 3 irAEs N (%)ORR
N (%)
Any grade irAEs N (%)Grade ≥ 3 irAEs N (%)
NSCLC (22)HIV (12)1(13)2(25)2(25)3(75)1(25)0
HBV/HCV(10)1(14)4(57)2(29)2(67)1(33)1(33)
HCC (17)HBV/HCV(16)3(19)7(44) b4(25)b 
  1. aResponse evaluable patients
  2. bTwo patients with baseline grade ≥ 2 hepatitis